Support great content
Help us bring you the AM insights that matter
BiomaterialsBioprintingPress Releases

Aprecia Pharmaceuticals and Cycle Pharmaceuticals partner to develop 3D printed orphan drugs

Aprecia Pharmaceuticals,  a company specializing in the 3D printing of pharmaceuticals, and Cycle Pharmaceuticals, signed a partnership agreement to develop and commercialize orphan drugs using three-dimensionally printed (“3DP”) technology. An orphan drug is a pharmaceutical agent that has been developed specifically to treat a rare medical condition, the condition itself being referred to as an orphan disease.

The planned products will deliver quality-of-life improvements versus existing, approved orphan drugs, and will achieve this by utilizing Aprecia’s proprietary 3DP ZipDose Technology platform. ZipDose is the only three-dimensional printing technology used in a pharmaceutical drug product approved by the U.S. Food and Drug Administration.

“Many rare disease patients do not have a treatment option at all. For those rare diseases where there is an approved pharmaceutical treatment, patients continue to be burdened by sub-optimal drug formulations. Aprecia’s ZipDose 3DP technology can formulate fast-melt pharmaceutical products, incorporating significantly higher amounts of active pharmaceutical ingredient than any other fast-melt technology on the market. As such, this advanced technology can uniquely overcome both pill burden and dysphagia – swallowing difficulties – both of which are life-long, daily issues for so many rare disease patients.” Antonio Benedetti, CEO of Cycle.

Aprecia expects to use its ZipDose Technology to transform the way people take medicine. Its first innovation, ZipDose Technology can be combined with a wide variety of active pharmaceutical ingredients to create rapidly disintegrating oral dosage forms that are easy to take and easy to administer. Aprecia is committed to enhancing the patient experience through novel approaches to drug delivery that address unmet treatment needs to eliminate patient suffering and caregiver burden.

“We are excited to work with the Cycle team, and we see important synergies in the companies’ shared mission to address unmet needs in patient care,” said Don Wetherhold, CEO of Aprecia. “Cycle specializes in orphan drugs – they have proven that they can deliver quality-of-life improvements to rare disease patients around the world. Aprecia is fully committed to applying its ZipDose 3DP printing technology to address real-world, daily issues faced by rare disease patients,” he continued.

Cycle Pharmaceuticals is a Cambridge-based pharmaceutical company that optimizes and increases access to existing pharmaceuticals. Specifically, Cycle focuses on three areas of pharmaceutical development: improving orphan drugs, which treat the under-served rare disease patient community; reinstating drug products that have been previously marketed; working with our academic and other partners to extend pharmaceuticals to new medical areas where there is clear unmet need.

Davide Sher

Since 2002, Davide has built up extensive experience as a technology journalist, market analyst and consultant for the additive manufacturing industry. Born in Milan, Italy, he spent 12 years in the United States, where he completed his studies at SUNY USB. As a journalist covering the tech and videogame industry for over 10 years, he began covering the AM industry in 2013, first as an international journalist and subsequently as a market analyst for leading US-firm SmarTech Analysis, focusing on the additive manufacturing industry and relative vertical markets. In 2016 he Co-founded London-based 3dpbm. Today the company publishes the leading news and insights websites 3D Printing Media Network and Replicatore, as well as 3D Printing Business Directory, the largest global directory of companies in the additive manufacturing industry.

Related Articles

Back to top button

We use cookies to give you the best online experience. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • PHPSESSID
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services
Close
Close

STAY AHEAD

OF THE CURVE

Join industry leaders and receive the latest insights on what really matters in AM!

This information will never be shared with 3rd parties

I’ve read and accept the privacy policy.*

WELCOME ON BOARD!